Niacin AIM HIGH study: Difference between revisions
| Line 6: | Line 6: | ||
The results of the '''AIM HIGH study''' were recently presented in [[AHA]] 2011 held at Orlando, Florida. The study hypothesis was that raising [[HDL]] "good" [[cholesterol]] by adding [[Niaspan]] (extended release [[niacin]]) to [[simvastatin]] would provide an additional 25% reduction in cardiovascular events in patients with established cardiovascular disease and well-controlled [[LDL]] "bad" cholesterol levels. However, an early termination of the study was done as an [[interim analysis]] found that combination therapy did not result in an additional reduction in cardiovascular events beyond treatment with simvastatin in the patients with well-controlled LDL cholesterol. The inclusion criteria was very tight (small % of high-risk patients who reach their guideline-recommended lipid treatment goals) thus decreasing the external validity or generalizability. Thus, the results from the study should not be applied beyond the patient population studied. | The results of the '''AIM HIGH study''' were recently presented in [[AHA]] 2011 held at Orlando, Florida. The study hypothesis was that raising [[HDL]] "good" [[cholesterol]] by adding [[Niaspan]] (extended release [[niacin]]) to [[simvastatin]] would provide an additional 25% reduction in cardiovascular events in patients with established cardiovascular disease and well-controlled [[LDL]] "bad" cholesterol levels. However, an early termination of the study was done as an [[interim analysis]] found that combination therapy did not result in an additional reduction in cardiovascular events beyond treatment with simvastatin in the patients with well-controlled LDL cholesterol. The inclusion criteria was very tight (small % of high-risk patients who reach their guideline-recommended lipid treatment goals) thus decreasing the external validity or generalizability. Thus, the results from the study should not be applied beyond the patient population studied. | ||
==AIM HIGH study== | ==AIM HIGH study <ref name="pmid22085343">{{cite journal| author=| title=Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. | journal=N Engl J Med | year= 2011 | volume= | issue= | pages= | pmid=22085343 | doi=10.1056/NEJMoa1107579 | pmc= | url= }} </ref>== | ||
* '''Funding''' - National Heart, Lung and Blood Institute (NHLBI) funded study. | * '''Funding''' - National Heart, Lung and Blood Institute (NHLBI) funded study. | ||
Revision as of 17:33, 24 November 2011
|
Lipoprotein Disorders Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]
Overview
The results of the AIM HIGH study were recently presented in AHA 2011 held at Orlando, Florida. The study hypothesis was that raising HDL "good" cholesterol by adding Niaspan (extended release niacin) to simvastatin would provide an additional 25% reduction in cardiovascular events in patients with established cardiovascular disease and well-controlled LDL "bad" cholesterol levels. However, an early termination of the study was done as an interim analysis found that combination therapy did not result in an additional reduction in cardiovascular events beyond treatment with simvastatin in the patients with well-controlled LDL cholesterol. The inclusion criteria was very tight (small % of high-risk patients who reach their guideline-recommended lipid treatment goals) thus decreasing the external validity or generalizability. Thus, the results from the study should not be applied beyond the patient population studied.
AIM HIGH study [1]
- Funding - National Heart, Lung and Blood Institute (NHLBI) funded study.
- Hypothesis - Raising HDL "good" cholesterol by adding Niaspan to simvastatin would provide an additional 25 percent reduction in cardiovascular outcomes in patients with established cardiovascular disease and well-controlled LDL "bad" cholesterol levels.
- Results - Early termination of the study as an interim analysis found that combination therapy did not result in an additional reduction in cardiovascular events beyond treatment with simvastatin in the patients with well-controlled LDL cholesterol and non-HDL-cholesterol.
- Patient population
- Patients with stable established cardiovascular disease with well-controlled lipid levels at the start of the study. Current treatment guidelines would not recommended additional lipid therapy for these patents.
- Majority of patients (94%) patients were taking statins (duration of statin therapy 1-5years)
- Limitations
- The inclusion criteria was very narrow (small percentage of high-risk patients who reach their guideline-recommended lipid treatment goals) thus decreasing the external validity or generalizability. Thus, the results from the study should not be applied beyond the patient population studied.
References
- ↑ "Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy". N Engl J Med. 2011. doi:10.1056/NEJMoa1107579. PMID 22085343.